KR20240045285A - 신규한 omni 115, 124, 127, 144-149, 159, 218, 237, 248, 251-253 및 259 crispr 뉴클레아제 - Google Patents
신규한 omni 115, 124, 127, 144-149, 159, 218, 237, 248, 251-253 및 259 crispr 뉴클레아제 Download PDFInfo
- Publication number
- KR20240045285A KR20240045285A KR1020247008131A KR20247008131A KR20240045285A KR 20240045285 A KR20240045285 A KR 20240045285A KR 1020247008131 A KR1020247008131 A KR 1020247008131A KR 20247008131 A KR20247008131 A KR 20247008131A KR 20240045285 A KR20240045285 A KR 20240045285A
- Authority
- KR
- South Korea
- Prior art keywords
- sequence
- seq
- rna
- molecule
- crispr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/102—Mutagenizing nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
- C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Mycology (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163232723P | 2021-08-13 | 2021-08-13 | |
| US63/232,723 | 2021-08-13 | ||
| PCT/US2022/074941 WO2023019269A2 (en) | 2021-08-13 | 2022-08-12 | Novel omni 115, 124, 127, 144-149, 159, 218, 237, 248, 251-253 and 259 crispr nucleases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20240045285A true KR20240045285A (ko) | 2024-04-05 |
Family
ID=85201029
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020247008131A Pending KR20240045285A (ko) | 2021-08-13 | 2022-08-12 | 신규한 omni 115, 124, 127, 144-149, 159, 218, 237, 248, 251-253 및 259 crispr 뉴클레아제 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20240376453A1 (https=) |
| EP (1) | EP4384610A4 (https=) |
| JP (1) | JP2024532784A (https=) |
| KR (1) | KR20240045285A (https=) |
| CN (1) | CN118103503A (https=) |
| AU (1) | AU2022325958A1 (https=) |
| CA (1) | CA3228373A1 (https=) |
| IL (1) | IL310732A (https=) |
| WO (1) | WO2023019269A2 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2024506608A (ja) | 2021-02-08 | 2024-02-14 | エメンドバイオ・インコーポレイテッド | Ｏｍｎｉ－１０３ ｃｒｉｓｐｒヌクレアーゼ |
| US12091688B2 (en) | 2021-02-08 | 2024-09-17 | Emendobio Inc. | OMNI-103 CRISPR nuclease |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018081728A1 (en) * | 2016-10-31 | 2018-05-03 | Emendobio Inc. | Compositions for genome editing |
| SG11201906297QA (en) * | 2017-03-24 | 2019-10-30 | Curevac Ag | Nucleic acids encoding crispr-associated proteins and uses thereof |
| WO2019165168A1 (en) * | 2018-02-23 | 2019-08-29 | Pioneer Hi-Bred International, Inc. | Novel cas9 orthologs |
| US20220213456A1 (en) * | 2019-04-30 | 2022-07-07 | Emendobio Inc. | Novel omni crispr nucleases |
| WO2021097271A1 (en) * | 2019-11-15 | 2021-05-20 | Assembly Biosciences, Inc. | Compositions comprising bacterial species and methods related thereto |
| EP4259159A4 (en) * | 2020-12-14 | 2025-04-09 | Emendobio Inc. | Biallelic knockout of trac |
| WO2022132765A1 (en) * | 2020-12-14 | 2022-06-23 | Emendobio Inc. | Biallelic knockout of b2m |
-
2022
- 2022-08-12 IL IL310732A patent/IL310732A/en unknown
- 2022-08-12 CA CA3228373A patent/CA3228373A1/en active Pending
- 2022-08-12 CN CN202280068825.XA patent/CN118103503A/zh active Pending
- 2022-08-12 KR KR1020247008131A patent/KR20240045285A/ko active Pending
- 2022-08-12 WO PCT/US2022/074941 patent/WO2023019269A2/en not_active Ceased
- 2022-08-12 EP EP22856851.5A patent/EP4384610A4/en active Pending
- 2022-08-12 US US18/683,113 patent/US20240376453A1/en active Pending
- 2022-08-12 JP JP2024508548A patent/JP2024532784A/ja active Pending
- 2022-08-12 AU AU2022325958A patent/AU2022325958A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3228373A1 (en) | 2023-02-16 |
| WO2023019269A2 (en) | 2023-02-16 |
| WO2023019269A3 (en) | 2023-04-13 |
| AU2022325958A1 (en) | 2024-03-21 |
| IL310732A (en) | 2024-04-01 |
| JP2024532784A (ja) | 2024-09-10 |
| US20240376453A1 (en) | 2024-11-14 |
| EP4384610A2 (en) | 2024-06-19 |
| CN118103503A (zh) | 2024-05-28 |
| EP4384610A4 (en) | 2025-07-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024050582A (ja) | 新規のｏｍｎｉ－５０ｃｒｉｓｐｒヌクレアーゼ | |
| JP2023531384A (ja) | 新規なｏｍｎｉ－５９、６１、６７、７６、７９、８０、８１及び８２クリスパーヌクレアーゼ | |
| KR20240043792A (ko) | 조작된 고충실도 omni-50 뉴클레아제 변이체 | |
| KR20240135610A (ko) | Omni-103 crispr 뉴클레아제-rna 복합체 | |
| WO2022226215A1 (en) | NOVEL OMNI 117, 140, 150-158, 160-165, 167-177, 180-188, 191-198, 200, 201, 203, 205-209, 211-217, 219, 220, 222, 223, 226, 227, 229, 231-236, 238-245, 247, 250, 254, 256, 257, 260 and 262 CRISPR NUCLEASES | |
| JP2023549139A (ja) | 新規ｏｍｎｉ－５０ ｃｒｉｓｐｒヌクレアーゼ－ｒｎａ複合体 | |
| KR20240045285A (ko) | 신규한 omni 115, 124, 127, 144-149, 159, 218, 237, 248, 251-253 및 259 crispr 뉴클레아제 | |
| KR20240135608A (ko) | 조작된 고활성 omni-79 뉴클레아제 변이체 | |
| KR20240133697A (ko) | 신규한 omni crispr 뉴클레아제 | |
| JP2024506608A (ja) | Ｏｍｎｉ－１０３ ｃｒｉｓｐｒヌクレアーゼ | |
| JP2023546694A (ja) | 新規のｏｍｎｉ５６、５８、６５、６８、７１、７５、７８及び８４ｃｒｉｓｐｒヌクレアーゼ | |
| KR20250130659A (ko) | Omni xl 1-22 crispr 뉴클레아제 | |
| HK40111655A (zh) | 新型omni 115、124、127、144-149、159、218、237、248、251-253和259 crispr核酸酶 | |
| KR20250130360A (ko) | Omni-355 crispr 뉴클레아제 | |
| HK40115104A (zh) | 工程化高活性omni-79核酸酶变体 | |
| CN117597142A (zh) | Omni 90-99、101、104-110、114、116、118-123、125、126、128、129和131-138 crispr核酸酶 | |
| HK40109205A (zh) | Omni90-99、101、104-110、114、116、118-123、125、126、128、129和131-138crispr核酸酶 | |
| HK40115053A (zh) | 新型omni crispr核酸酶 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| E13 | Pre-grant limitation requested |
Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |